The Role of Chitosan Oligosaccharide in Metabolic Syndrome: A Review of Possible Mechanisms

• Main Authors: Wenjing Tao, Geng Wang, Jintao Wei
• Format: Article
• Language: English
• Published: MDPI AG 2021-09-01
• Series: Marine Drugs
• Subjects: chitosan oligosaccharide; metabolic syndrome; obesity; diabetes; hypertension
• Online Access: https://www.mdpi.com/1660-3397/19/9/501

Metabolic syndrome, a cluster of metabolic disorders including central obesity, insulin resistance, hyperglycemia, dyslipidemia, and hypertension, has become a major public health problem worldwide. It is of great significance to develop natural products to prevent and treat metabolic syndrome. Chitosan oligosaccharide (COS) is an oligomer of chitosan prepared by the deacetylation of chitin, which is the second most abundant polymer in nature. In recent years, COS has received widespread attention due to its various biological activities. The present review will summarize the evidence from both in vitro and in vivo studies of the beneficial effects of COS on obesity, dyslipidemia, diabetes mellitus, hyperglycemia, and hypertension, and focus attention on possible mechanisms of the prevention and treatment of metabolic syndrome by COS.